

Detection of Helicobacter Pylori in Ulcerative Colitis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. [Know the risks and potential benefits](#) of clinical studies and talk to your health care provider before participating. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT03172000

Recruitment Status : Recruiting

Sponsor:

Tanta University

Information provided by (Responsible Party):

Tanta University

- [Study Details](#)
- [Tabular View](#)
- [No Results Posted](#)
- [Disclaimer](#)
- [How to Read a Study Record](#)

Study Description

Go to

Brief Summary:

Helicobacter pylori (H. pylori) infection is one of the most common infectious diseases in humans.

Condition or disease	Intervention/treatment	Phase
Inflammatory Bowel Diseases	Diagnostic Test: Colonoscopy and biopsy	Not Applicable

Detailed Description:

Several bacterial and viral agents may have a role in the aetiology of IBD. In theory, H. pylori infection could be involved in IBD by inducing alterations in gastric and/or intestinal permeability or by causing immunological derangements resulting in absorption of antigenic material and autoimmunity via various immunological pathways.

Study Design

Go to

Study Type : Interventional (Clinical Trial)

Estimated Enrollment : 60 participants

Allocation: Non-Randomized

Intervention Model: Parallel Assignment

Masking: None (Open Label)

Primary Purpose: Diagnostic

Official Title: Detection of Helicobacter Pylori in Colonic Tissue in Newly Diagnosed Ulcerative Colitis Patients

Actual Study Start Date : March 1, 2017

Estimated Primary Completion Date : August 2019

Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine



[Genetics Home Reference](#) related topics: [Ulcerative colitis](#)

[MedlinePlus](#) related topics: [Biopsy Ulcerative Colitis](#)

[U.S. FDA Resources](#)

Arms and Interventions

Go to

Arm	Intervention/treatment
Active Comparator: Colonoscopy and biopsy IBD patients	Diagnostic Test: Colonoscopy and biopsy Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
No Intervention: Colonoscopic biopsy Non IBD patients	

colonoscopic biopsy	
---------------------	--

Outcome Measures

Go to

Primary Outcome Measures :

1. Number of patients with Helicobacter [Time Frame: 6 months]

Number of patients with Helicobacter

Eligibility Criteria

Go to

Information from the National Library of Medicine



Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies](#).

Ages Eligible for Study: Child, Adult, Older Adult
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- newly diagnosed ulcerative colitis

Exclusion Criteria:

- Other diagnosis

Contacts and Locations

Go to

Information from the National Library of Medicine



To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number):
NCT03172000

Contacts

Contact: Sherief Abd-Elsalam, MD	00201147773440	Sheriefabdelsalam@yahoo.com
Contact: sherief Abd-Elsalam, Consultant	00201147773440 ext 002	sheriefabdelsalam@yahoo.com

Locations

Egypt

Tanta university - faculty of medicine Cairo, Egypt	Recruiting
Contact: Sherief M Abdelsalam, lecturer 00201095159522	Sheriefabdelsalam@yahoo.com

Sponsors and Collaborators

Tanta University

Investigators

Principal Investigator:	Loai Mansour, MD	Tanta University Faculty of Medicine
Principal Investigator:	Ferial El-kalla, MD	Tanta university Faculty of Medicine
Study Director:	Abdelrahman Kobtan, MD	Tanta University Faculty of Medicine
Study Chair:	Sherief Abd-Elsalam, MD	Tanta University Faculty of Medicine

More Information
Go to

Responsible Party: Tanta University
ClinicalTrials.gov Identifier: [NCT03172000](#) [History of Changes](#)
Other Study ID Numbers: IBD Helicobacter
First Posted: May 31, 2017 [Key Record Dates](#)
Last Update Posted: May 31, 2017
Last Verified: May 2017

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No

Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Colitis	Gastrointestinal Diseases
Colitis, Ulcerative	Digestive System Diseases
Inflammatory Bowel Diseases	Colonic Diseases
Gastroenteritis	Intestinal Diseases